All news

PDSB jumps on JAMA data and Nant Capital PIPE

Alpha Vantage · StocksToTrade · · AI-summarised by FinFlash

PDS Biotechnology shares jumped 13.08% after Phase 2 data for its HPV16-targeted immunotherapy PDS0101 was published in JAMA Oncology, showing a 36% objective response rate and 39.3-month median overall survival. The company also secured an

Read original source

PDSB company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.